CapsoVision, Inc. (CV)
NASDAQ:CV
Want to see CV full AI Analyst Report?
CV Stock Chart & Stats
$13.23
--
Market closed
$13.23
--
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)45.47K
Market Cap
$349.37M
Enterprise Value$340.15M
Total Cash (Recent Filing)$10.11M
Total Debt (Recent Filing)$887.00K
Price to Earnings (P/E)―
Beta-1.40
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding49,838,867
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue25.10
Enterprise Value/Gross Profit47.42
Enterprise Value/Ebitda-13.63
Forecast
1Y Price Target
$10.50Price Target Upside-20.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$19.07M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsSustained high revenue growth with stable mid-50% gross margins indicates underlying product demand and unit economics that can support scaling. Durable gross margins provide room to invest in commercialization and R&D while preserving a realistic path to structural profitability as volumes grow.
Operating Improvement Toward BreakevenNear-breakeven operating performance signals improving cost structure and operational leverage. If the company sustains this trend while growing revenue, it reduces reliance on capital markets, improves cash flow dynamics, and increases odds of durable profitability over the medium term.
Secured Upgraded Sensor SupplyLocking enhanced image sensor development with Canon strengthens product competitive position and supports regulatory submissions. Preserving the payment and purchase framework maintains predictable supply and cost structure, a lasting advantage for clinical validation and commercial adoption.
Bears Say
High Cash BurnConsistent, large negative operating and free cash flows require ongoing external financing and create dilution risk. Cash burn that materially outpaces revenue weakens financial flexibility, constrains sustained investment in trials and commercialization, and heightens execution risk over months.
Accumulated Losses / Weak Capital BaseSignificant accumulated losses and volatile equity undermine balance-sheet resilience and raise the probability of future equity raises. This structural weakness can force unfavorable financing terms, dilute shareholders, and limit long-term strategic flexibility for product development.
Regulatory And Clinical DelaysStopping the original FDA pathway and expanding a new pivotal study delays commercialization, increases trial and development costs, and extends time to reimbursement and scale. These structural delays raise execution and funding risk until pivotal data and regulatory clearance are achieved.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $349.37M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is May 14, 2026 which is in 6 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.015.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Overvalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 49,838,867 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -0.266%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Company Description
CapsoVision, Inc.
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
CV Earnings Call
Q4 2026
0:00 / 0:00
CV Stock 12 Month Forecast
Average Price Target
$10.50
▼(-20.63% Downside)
Technical Analysis
Ownership Overview
2.75% Insiders
0.53% Mutual Funds
0.02% Other Institutional Investors
92.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---